Renal cell carcinoma is the third most prevalent kind of urologic cancer. Because the first symptoms are often vague and late, the phases are often advanced when detected. As compensation, the discovery of RCC by abdominal imaging modalities used for other medical objectives is a fact that favors a reduction in the stage of newly detected tumors. As a result, finding new predictive biomarkers for RCC diagnosis, progression, and the prognosis is critical. Several studies have shown that microRNAs (miRNAs) have a role in the specific situation of urologic malignancies and that changes in miRNA levels play a function in the genesis, development, and generation of renal cancer metastases.

Researchers reviewed the most recent preliminary clinical studies on the significance of urine miRNA profiling in RCC, including an assessment of its utility as a potential biomarker for RCC diagnosis, prognosis, and follow-up.